These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 34845459)

  • 1. Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era.
    Barnard RC; Davies NG; ; Jit M; Edmunds WJ
    medRxiv; 2022 May; ():. PubMed ID: 34845459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era.
    Barnard RC; Davies NG; ; Jit M; Edmunds WJ
    Nat Commun; 2022 Aug; 13(1):4879. PubMed ID: 35986002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.
    Vattiatio G; Lustig A; Maclaren OJ; Plank MJ
    Epidemics; 2022 Dec; 41():100657. PubMed ID: 36427472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voluntary risk mitigation behaviour can reduce impact of SARS-CoV-2: a real-time modelling study of the January 2022 Omicron wave in England.
    Brooks-Pollock E; Northstone K; Pellis L; Scarabel F; Thomas A; Nixon E; Matthews DA; Bowyer V; Garcia MP; Steves CJ; Timpson NJ; Danon L
    BMC Med; 2023 Jan; 21(1):25. PubMed ID: 36658548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of the potential impact of the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.
    Vattiato G; Maclaren O; Lustig A; Binny RN; Hendy SC; Plank MJ
    Infect Dis Model; 2022 Jun; 7(2):94-105. PubMed ID: 35434431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups.
    Kelly SL; Le Rutte EA; Richter M; Penny MA; Shattock AJ
    Infect Dis Ther; 2022 Oct; 11(5):2045-2061. PubMed ID: 36094720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022.
    Klaassen F; Chitwood MH; Cohen T; Pitzer VE; Russi M; Swartwood NA; Salomon JA; Menzies NA
    Clin Infect Dis; 2023 Aug; 77(3):355-361. PubMed ID: 37074868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of reported infection and reinfection of SARS-CoV-2 in England.
    Keeling MJ
    J Theor Biol; 2023 Jan; 556():111299. PubMed ID: 36252843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study).
    Kiss Z; Wittmann I; Polivka L; Surján G; Surján O; Barcza Z; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Pálosi M; Szlávik J; Schaff Z; Szekanecz Z; Müller C; Kásler M; Vokó Z
    Front Immunol; 2022; 13():905585. PubMed ID: 35812442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
    Front Immunol; 2022; 13():919408. PubMed ID: 35935993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021.
    Johnson AG; Amin AB; Ali AR; Hoots B; Cadwell BL; Arora S; Avoundjian T; Awofeso AO; Barnes J; Bayoumi NS; Busen K; Chang C; Cima M; Crockett M; Cronquist A; Davidson S; Davis E; Delgadillo J; Dorabawila V; Drenzek C; Eisenstein L; Fast HE; Gent A; Hand J; Hoefer D; Holtzman C; Jara A; Jones A; Kamal-Ahmed I; Kangas S; Kanishka F; Kaur R; Khan S; King J; Kirkendall S; Klioueva A; Kocharian A; Kwon FY; Logan J; Lyons BC; Lyons S; May A; McCormick D; ; Mendoza E; Milroy L; O'Donnell A; Pike M; Pogosjans S; Saupe A; Sell J; Smith E; Sosin DM; Stanislawski E; Steele MK; Stephenson M; Stout A; Strand K; Tilakaratne BP; Turner K; Vest H; Warner S; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):132-138. PubMed ID: 35085223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
    Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
    Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological characteristics of 17 imported patients infected with SARS-CoV-2 Omicron variant.
    Liu X; Chen M; Zhou Z; Chen D; Mo J; Liu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):344-351. PubMed ID: 35545327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents.
    Canaday DH; Oyebanji OA; White E; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Sheehan ML; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S
    EBioMedicine; 2022 Jun; 80():104066. PubMed ID: 35605428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among Persons in a Social Network Attending a Convention - New York City, November 18-December 20, 2021.
    Smith-Jeffcoat SE; Pomeroy MA; Sleweon S; Sami S; Ricaldi JN; Gebru Y; Walker B; Brady S; Christenberry M; Bart S; Vostok J; Meyer S; Seys S; Markelz A; Ditto N; Newbern V; Thomas FJ; Thomas D; Cabredo E; Kellner S; Brown VR; Tate JE; Kirking HL
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):238-242. PubMed ID: 35176004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
    Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA
    Front Immunol; 2022; 13():882918. PubMed ID: 35958601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.